.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA05_Aflibercept.Aflibercept .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA05_Aflibercept.Aflibercept| name: | Aflibercept |
| ATC code: | S01LA05 | route: | intravitreal |
| n-compartments | 2 |
Aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor, used primarily for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and other retinal vascular diseases. It is approved for intravitreal use in ophthalmology.
Pharmacokinetic parameters after a single intravitreal injection of aflibercept 2 mg in adult patients with neovascular AMD; population includes both sexes, typically age >50 years.
Hoy, SM (2017). Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion. Drugs & aging 34(5) 393–400. DOI:10.1007/s40266-017-0458-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28365905
Nagaoka, K, et al., & Aizawa, K (2025). Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis. International journal of molecular sciences 26(2) –. DOI:10.3390/ijms26020556 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39859273